<DOC>
	<DOC>NCT00810979</DOC>
	<brief_summary>The purpose of this study is to determine whether SLx-4090 in combination with statin therapy will reduce LDL-C in patients with hyperlipidemia more effectively than statin therapy alone.</brief_summary>
	<brief_title>Comparison of SLx-4090 Combined With Statin Therapy Versus Statin Alone in Reducing LDL-C in Patients With Hyperlipidemia</brief_title>
	<detailed_description>1. LDL-C after 12 weeks of treatment 2. Safety and tolerability 3. Plasma levels of SLx-4090</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>LDLC &gt; or = 100 mg/dL On stable statin therapy for at least 6 weeks Coronary heart disease or risk factors for CHD</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>